Gideon Bollag

Chan Zuckerberg Biohub San Francisco — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

67h-index30.5kcitations360works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(133), Protein Kinase Regulation and GTPase Signaling(50), Colorectal Cancer Treatments and Studies(49), Cancer Mechanisms and Therapy(46), Immune cells in cancer(37)

Publications360 total

Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders
Cancer Research·2026
RAF inhibitors activate the integrated stress response by direct activation of GCN2
Nature Communications·2025Open Access
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling
2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models
Nature Communications·2025· 1 citedOpen Access
Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity
Blood·2025Open Access
Abstract C024: CBP/EP300 inhibitor OPN-6602 in marginal zone lymphomas: preclinical activity as a single agent and in combination with BTK inhibition
Molecular Cancer Therapeutics·2025
OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC
Blood·2024· 1 cited
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
Blood·2024Open Access
RAF inhibitors activate the integrated stress response by direct activation of GCN2
2024· 2 citedOpen Access
Abstract 7201: Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models
Cancer Research·2024
Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
Cancer Research·2024· 2 cited
Abstract 7264: OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models
Cancer Research·2024· 2 cited
Abstract C085: OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription, including MYC, in mCRPC
Molecular Cancer Therapeutics·2023
Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- <i>Versus</i>-Host-Disease Via Modulating the CXCR5/CXCL13 Axis
Blood·2023Open Access
Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation
JCI Insight·2023· 5 citedOpen Access
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
JCO Precision Oncology·2023· 9 cited
Abstract 6396: BET inhibition alleviates T-cell dysfunction in chronic lymphocytic leukemia
Cancer Research·2023
Supplemental Tables 1-3 from Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas &lt;i&gt;In Vivo&lt;/i&gt; and &lt;i&gt;Ex Vivo&lt;/i&gt;
2023Open Access
Supplementary Figures &amp; Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
page 1 of 18Next →

Frequent Co-authors

Brian L. West(14), Prabha N. Ibrahim(10), Chao Zhang(8), Gaston Habets(8), Jiazhong Zhang(7), Elizabeth A. Burton(7), Hoa Nguyen(7), Kam Y. J. Zhang(7), K. B. Nolop(7), James Tsai(6), Daniel W. Fong(6), Frank McCormick(6), Peter Hirth(5), Garson Tsang(5), Ben Powell(5), Rafe Shellooe(5), Adhirai Marimuthu(5), Dean R. Artis(5), Joseph Schlessinger(5), Richard J. Lee(5)